We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Allergan plc | NYSE:AGN | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 193.02 | 0 | 01:00:00 |
From May 2019 to May 2024
By Chris Wack
Allergan PLC (AGN) said Monday that its Warner Chilcott and Watson subsidiaries have reached resolutions with all plaintiffs, including a class of direct purchasers, individual direct purchasers that previously opted out of the direct purchaser class, and a class of indirect purchasers of Loestrin 24 Fe and Minastrin 24 Fe.
The company said the settlement concludes the previously disclosed antitrust litigation in the U.S. District Court for the District of Rhode Island.
Allergan said the settlements make no admission of wrongdoing on the part of the company and resolve the litigation that was scheduled to go to trial Monday.
The company said Warner Chilcott and Watson will pay about $300 million under the settlement agreements, which are subject to court approval of the agreements with the direct and indirect purchaser classes.
Allergan said it will take a pre-tax charge of $300 million to its fourth quarter earnings.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 06, 2020 07:24 ET (12:24 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Allergan Chart |
1 Month Allergan Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
